INFINIUM

Infinium Pharmachem Share Price

₹287.45 -0.25 (-0.09%)

19 Jul, 2025 01:20

SIP TrendupStart SIP in INFINIUM

Start SIP

Performance

  • Low
  • ₹285
  • High
  • ₹294
  • 52 Week Low
  • ₹178
  • 52 Week High
  • ₹393
  • Open Price₹294
  • Previous Close₹288
  • Volume2,500

Investment Returns

  • Over 1 Month -3.52%
  • Over 3 Month + 21.54%
  • Over 6 Month -4.5%
  • Over 1 Year + 26.05%
SIP Lightning

Smart Investing Starts Here Start SIP with Infinium Pharmachem for Steady Growth!

Invest Now

Infinium Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 49.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 400
  • P/B Ratio
  • 6.3
  • Average True Range
  • 11.97
  • EPS
  • 5.23
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.55
  • RSI
  • 48.95
  • MFI
  • 33.32

Infinium Pharmachem Financials

Infinium Pharmachem Technicals

EMA & SMA

Current Price
₹287.45
-0.25 (-0.09%)
pointer
  • stock-down_img
  • Bearish Moving Average 7
  • stock-up_img
  • Bullish Moving Average 9
  • 20 Day
  • ₹287.88
  • 50 Day
  • ₹288.10
  • 100 Day
  • ₹283.74
  • 200 Day
  • ₹276.14

Resistance and Support

288.82 Pivot Speed
  • R3 301.63
  • R2 297.82
  • R1 292.63
  • S1 283.63
  • S2 279.82
  • S3 274.63

What's your outlook on Infinium Pharmachem?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Infinium Pharmachem Ltd has an operating revenue of Rs. 352.85 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 7% is okay, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 69 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 145 indicates it belongs to a poor industry group of Comml Svcs-Healthcare and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Infinium Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-28 Audited Results & Others To consider other business matters. (Revised) issue in the ratio of 1:1 of Rs. 10/-.
2024-11-14 Quarterly Results & Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2024-05-29 Audited Results
2023-10-27 Quarterly Results
2023-08-02 Bonus issue
Date Purpose Remarks
2023-09-13 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Infinium Pharmachem F&O

Infinium Pharmachem Shareholding Pattern

65.24%
32%
2.76%

About Infinium Pharmachem

  • NSE Symbol
  • INFINIUM
  • BSE Symbol
  • Managing Director
  • Mr. Sanjaykumar Viththalbhai Patel
  • ISIN
  • INE0MRE01011

Similar Stocks to Infinium Pharmachem

Infinium Pharmachem FAQs

Infinium Pharmachem share price is ₹287 As on 19 July, 2025 | 01:06

The Market Cap of Infinium Pharmachem is ₹400 Cr As on 19 July, 2025 | 01:06

The P/E ratio of Infinium Pharmachem is 49.1 As on 19 July, 2025 | 01:06

The PB ratio of Infinium Pharmachem is 6.3 As on 19 July, 2025 | 01:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23